Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

BTAI

BioXcel Therapeutics (BTAI)

BioXcel Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:BTAI
DateTimeSourceHeadlineSymbolCompany
06/25/20247:00AMGlobeNewswire Inc.BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI™ (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or SchizophreniaNASDAQ:BTAIBioXcel Therapeutics Inc
06/18/20249:27PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BTAIBioXcel Therapeutics Inc
06/18/20249:26PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BTAIBioXcel Therapeutics Inc
06/18/20249:25PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BTAIBioXcel Therapeutics Inc
06/18/20249:24PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BTAIBioXcel Therapeutics Inc
06/17/20243:13PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BTAIBioXcel Therapeutics Inc
06/17/20242:34PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BTAIBioXcel Therapeutics Inc
06/17/20241:46PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BTAIBioXcel Therapeutics Inc
06/17/20241:04PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BTAIBioXcel Therapeutics Inc
06/11/20247:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BTAIBioXcel Therapeutics Inc
06/11/20247:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BTAIBioXcel Therapeutics Inc
06/04/20247:30AMEdgar (US Regulatory)Form 424B7 - Prospectus [Rule 424(b)(7)]NASDAQ:BTAIBioXcel Therapeutics Inc
05/28/20247:00AMGlobeNewswire Inc.BioXcel Therapeutics to Present at Jefferies Global Healthcare ConferenceNASDAQ:BTAIBioXcel Therapeutics Inc
05/21/20247:00AMGlobeNewswire Inc.BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual MeetingNASDAQ:BTAIBioXcel Therapeutics Inc
05/09/20249:05AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BTAIBioXcel Therapeutics Inc
05/09/20247:12AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BTAIBioXcel Therapeutics Inc
05/09/20247:00AMGlobeNewswire Inc.BioXcel Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:BTAIBioXcel Therapeutics Inc
04/25/20247:00AMGlobeNewswire Inc.BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024NASDAQ:BTAIBioXcel Therapeutics Inc
04/24/202410:30AMGlobeNewswire Inc.BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual MeetingNASDAQ:BTAIBioXcel Therapeutics Inc
04/22/20247:00AMGlobeNewswire Inc.BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market PotentialNASDAQ:BTAIBioXcel Therapeutics Inc
04/10/20247:00AMGlobeNewswire Inc.BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s DementiaNASDAQ:BTAIBioXcel Therapeutics Inc
03/25/20247:00AMGlobeNewswire Inc.BioXcel Therapeutics Announces $25 Million Registered Direct OfferingNASDAQ:BTAIBioXcel Therapeutics Inc
03/15/20247:00AMGlobeNewswire Inc.BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual DexmedetomidineNASDAQ:BTAIBioXcel Therapeutics Inc
03/12/20247:00AMGlobeNewswire Inc.BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023NASDAQ:BTAIBioXcel Therapeutics Inc
03/01/20247:00AMGlobeNewswire Inc.BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024NASDAQ:BTAIBioXcel Therapeutics Inc
02/14/20247:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BTAIBioXcel Therapeutics Inc
02/13/20249:00AMGlobeNewswire Inc.BioXcel Therapeutics Announces Termination of Proposed Public OfferingNASDAQ:BTAIBioXcel Therapeutics Inc
02/12/202412:45PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:BTAIBioXcel Therapeutics Inc
02/12/20247:14AMGlobeNewswire Inc.BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)NASDAQ:BTAIBioXcel Therapeutics Inc
02/08/20245:27PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:BTAIBioXcel Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:BTAI